Insider Cluster (2 insiders) ·Filed May 1, 2026

ALKS

Alkermes plc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $368K total
Actionable Insight • Neutral

This cluster is too small to warrant a trade signal. Monitor for any upcoming material filings (earnings, pipeline updates, M&A) that could explain the sales, but the dollar amounts are routine portfolio management. No action needed.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
ALKS ▲ +58.55% at T+60d
NEUTRAL call ✓ call won +58.55% · α vs SPY +55.99% · entry $33.26 → $52.73
Entry anchored
Apr 30, 03:59 PM ET
via exchange tick
T+1d
+2.65%
call +2.65% · α +2.99%
$34.14
settled 5mo ago
T+5d
+6.44%
call +6.44% · α +4.10%
$35.40
settled 5mo ago
T+20d
+27.10%
call +27.10% · α +21.82%
$42.27
settled 4mo ago
T+60d
+58.55%
call +58.55% · α +55.99%
$52.73
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Two Alkermes insiders — the EVP/CLO and EVP R&D/Chief Medical Officer — sold a combined $368K in open-market stock over four days, with the CMO also exercising options. The total sales represent ~0.007% of Alkermes' $5.5B market cap, a trivial amount that carries no material signal. Historical calibration on this ticker shows prior neutral calls underperformed, but this cluster is too small to drive a directional read.

Key Financial Metrics

Direction
selling
Total Value
$368.1K
Insiders
2

Key Facts

  • Two insiders sold a combined $368K in open-market shares over 4 trading days
  • EVP/CLO David Gaffin sold 2,034 shares at $33.20 for $68K on May 4
  • EVP R&D/CMO Craig Hopkinson sold 9,000 shares at $33.40 for $301K on May 1, after exercising options
  • Total sales represent ~0.007% of Alkermes' $5.5B market cap — well below the 0.1% materiality threshold
  • No insider buying was reported in the cluster window

Financial Impact

Total insider sales of $368K, or 0.007% of market cap — economically trivial

Risk Factors

  • Insider selling could accelerate if a negative catalyst emerges, but this cluster alone is not predictive

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (24 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ALKS-1777941791289
18 reports for ALKS
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +25.88%May 12, 2026
Filters
Rows
Reports for ALKS — sortable, filterable
TypeNow
Sep 16, 2026
16d ago
8-K
NEUTRAL ★ 2/10
$46.07 $42.13▼ −8.55%▼ −11.12%$41.64 (−9.62%)
Sep 3, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$46.10 $45.83▼ −0.59%▲ +0.62%$41.64 (−9.67%)
Aug 3, 2026
8w ago
Insider Cluster
BEARISH ★ 4/10
$49.67 $49.21▲ +0.93%▲ +0.83%$41.64 (+16.17%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.64 (−16.17%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.64 (−16.17%)
Jul 28, 2026
9w ago
8-K
BEARISH ★ 6/10
$50.50 $49.53▲ +1.92%▲ +4.19%$41.64 (+17.54%)
Jul 8, 2026
12w ago
8-K
NEUTRAL ★ 3/10
$54.29 $51.60▼ −4.95%▼ −5.82%$41.64 (−23.30%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.14 $51.94▼ −5.80%▼ −6.29%$41.64 (−24.48%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$42.80 $44.28▲ +3.46%▲ +2.89%$41.64 (−2.71%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$41.19 $44.29▲ +7.53%▲ +10.50%$41.64 (+1.10%)
Showing 10 of 18

US Market Status

Market Open — Closes in 2h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 5, 2026